Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
about
Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionLow body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse eventsImpact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Population pharmacokinetics of emtricitabine in HIV-1-infected adult patientsRenal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patientsLow cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adultsPractical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Tenofovir induced Fanconi syndrome: a possible pharmacokinetic interaction.Clinical pharmacokinetics of antiretroviral drugs in older persons.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Renal function with use of a tenofovir-containing initial antiretroviral regimenPopulation pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.p16INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects.Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.Pharmacokinetics of fixed-dose combination of tenofovir disoproxil fumarate, lamivudine, and efavirenz: results of a randomized, crossover, bioequivalence study.Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study.Population pharmacokinetics of tenofovir in AIDS patients.Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
P2860
Q28481276-35E124B6-4A6C-476B-A758-B62370D8EEE0Q28535587-F59D334F-7B12-42DC-AC01-FE0059E5E188Q31028855-7BC1E908-8CD2-4513-9068-4B26E75E1841Q33622825-353FC801-AB09-4860-84D4-39FA5DF58BD6Q34126724-8E749044-E37A-4A2A-B921-5386E5F0C6AEQ34573789-8DA4C7E5-4FE2-4330-8607-DD75AD62221BQ34658079-697292E6-212A-4C55-A6A1-55CC948DC753Q35363649-67D829E8-A8AF-4CE2-8EAF-95DECE4A4BA1Q35607723-53F8B8E2-ADAE-498E-A72F-EBC9BD2A29B1Q35823231-0DF30581-83D6-445A-B814-179D3AD8DBE2Q36075954-7387A481-F455-4510-B855-D0F7C1B1560CQ36188725-DD621F4A-2C42-4BA6-BDE2-34CA26683983Q36243626-D30073C1-1FA5-4591-838A-3C13CB67C144Q36430073-96C0C18B-1433-4583-A064-32BA562B2AF4Q36650454-DFC38797-4E27-48CF-9AF1-CC2BD4C615D9Q36727960-B186E918-17D9-47B5-B6FC-FDBCBC1B3BB8Q36757558-C9577E89-1664-48D4-B6EF-B571A9E8C334Q36845126-C6C9129A-DFF4-40F3-BB66-F44F5B9FD26DQ36865491-BBD0115F-49CF-4EAD-A7C3-18B0B2979077Q36905884-9028ED83-73FB-46BA-AF36-0F16F297F87FQ37203867-635F65EB-1F8A-4B94-BC57-F4E9F5FAE163Q37210864-35237DDF-DCEC-425E-83EE-2B2EED81A5ABQ37215065-23CD4AEB-8FAF-4CF2-B470-972D689C41CDQ37224902-503B5D44-A2A8-4F12-BE4D-123BF3224CFFQ37245017-3F3D5E69-657E-4860-8E04-00CB36D70BEFQ37660709-038EC534-294D-4512-8621-A260E2364ABFQ37713060-74926B59-FA9D-4E63-AD8C-38CC5E27AEE9Q38798813-CDE2CAA5-70FC-414A-A215-98E5E96A62E3Q39107383-3A8B8FE8-3CC7-4408-A877-504C02436072Q39673548-BDFCB585-399E-47CD-9E8C-1823FB0CDE9CQ40100382-CC87C366-3280-4EC2-8A62-E85FCC25460FQ41204065-E3E0EEE6-BADA-4068-AE48-FD0B744911F5Q42279687-58C8B85D-85EE-467F-9FFE-5F6DF49383AFQ43013478-A3938FFB-0C99-4D3F-A781-02F03F41824FQ45349377-ADCBA063-2462-4C1C-B5D2-CDC4C8924CC9Q46261840-D5A429D8-75D5-4E74-9436-162BEEED3E36Q46432681-D5E242C7-76A3-4382-B6A7-9908486CF543Q46697094-9A6237B4-7BD1-4241-A57D-C6D38BBB8195Q47628152-8407FCFA-3B85-440C-B93D-58A7F6196A9CQ47633560-6309EA3B-C0A0-46F1-8408-34FC5DF38737
P2860
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Population pharmacokinetics of ...... active antiretroviral therapy.
@ast
Population pharmacokinetics of ...... active antiretroviral therapy.
@en
type
label
Population pharmacokinetics of ...... active antiretroviral therapy.
@ast
Population pharmacokinetics of ...... active antiretroviral therapy.
@en
prefLabel
Population pharmacokinetics of ...... active antiretroviral therapy.
@ast
Population pharmacokinetics of ...... active antiretroviral therapy.
@en
P2093
P2860
P1476
Population pharmacokinetics of ...... active antiretroviral therapy.
@en
P2093
Agnès Lillo-Le Louet
Anne Krivine
Anne Lescoat
Dominique Salmon
Elisabeth Rey
Gérard Pons
Jean-Marc Tréluyer
Laurence Moachon
Nicolas Dupin
Patrick Jaffray
P2860
P304
P356
10.1128/AAC.49.8.3361-3366.2005
P407
P577
2005-08-01T00:00:00Z